BioForce Nanosciences!
Seite 1 von 1 Neuester Beitrag: 29.12.06 10:19 | ||||
| Eröffnet am: | 29.12.06 10:19 | von: soros | Anzahl Beiträge: | 1 |
| Neuester Beitrag: | 29.12.06 10:19 | von: soros | Leser gesamt: | 1.565 |
| Forum: | Hot-Stocks | Leser heute: | 2 | |
| Bewertet mit: |  | |||
soros
December 18, 2006 - 8:30 AM EST
close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
BFNH 2.00 0.05
Today 5d 1m 3m 1y 5y 10y
BioForce Nanosciences, Inc. Places Nano eNabler(TM) Systems in Four Research Centers Across North America
AMES, Iowa, Dec. 18 /PRNewswire-FirstCall/ -- BioForce Nanosciences, Inc., a wholly owned subsidiary of BioForce Nanosciences Holdings, Inc. (OTC Bulletin Board: BFNH.OB), announced today the placement of its cutting-edge Nano eNabler(TM) molecular printer at four prestigious colleges and universities in the United States and Canada as part of its pilot placement program. This program consists of the placement of the Company's patented Nano eNabler(TM) device at approximately 20 key centers of research excellence, where it is operated by entrepreneurial researchers often termed 'early adopters.' This program is designed to position BioForce as a principal provider of practical tools and technologies for the nano/life sciences market and promote the conversion of these placements into sales.
Recently, the instrument has been installed in four locations: 1) California Institute for Quantitative Biomedical Research (QB3) at the University of California under the supervision of Tejal Desai, Ph.D; 2) the Department of Physics at McGill University in Montreal under the supervision of Peter Grutter, Ph.D.; 3) The Biofunctional Photonics Group at The Rowland Institute, Harvard University, under the supervision of Frank Vollmer, Ph.D. and Ozgur Sahin, Ph.D.; and 4) Boston University's Center for Nanoscience and Nanobiotechnology under the supervision of Dr. Mario Cambodi.
These placements are part of a larger BioForce Nanosciences, Inc. pilot program to gather feedback on the performance of the Nano eNabler system, and facilitate real-world applications of the instrument. BioForce Product Manager Michael Lynch says, 'The goal of the BioForce pilot placement program is to seek out groups of innovators working in micro and nanotechnologies, and provide them with early access to a new tool for their research. Their application development efforts and feedback concerning the features and performance of the Nano eNabler are invaluable to us. The supportive mission of all these institutions toward the industry makes this a perfect fit, and we are excited about the prospects for these mutually beneficial partnerships.'
BioForce's Kerry Frey, chief operating officer, says, 'This instrument allows researchers to create patterns of molecules that direct cell growth, functionalize nano/biosensors, and create new therapeutic microdevices. As we move into 2007, BioForce is poised to help researchers discover additional uses for the Nano eNabler technology.' By the end of 2006, BioForce Nanosciences anticipates having shipped 20 systems.
Information on the institutions where recent placements have taken place:
* California Institute for Quantitative Biomedical Research (QB3) at the
University of California in San Francisco, CA-studies focus on the
design, fabrication, and making the essential connections between
structure and function of biomolecules at the micro/nanoscale to human
physiology and pathophysiology at the macroscale.
* Department of Physics at McGill University in Montreal, QC Canada-McGill
University's Department of Physics offers a rich research environment
that includes the availability of advanced probes and sensors, fast
imaging and correlation spectroscopies, and the access to atomic
manipulation and microfabrication facilities.
* The Biofunctional Photonics Group at The Rowland Institute, Harvard
University, Cambridge, MA-the Biofunctional Photonics Group interfaces
applied physics with biochemistry to design and fabricate photonic and
microfluidic circuits for biodetection, manipulation, spectroscopy, and
biological analysis.
* Boston University's Center for Nanoscience and Nanobiotechnology-
advances academic and technological research and development by
extending discoveries in nanoscale materials and platforms toward
applications that examine and seek to understand and manipulate
biological systems.
About BioForce Nanosciences, Inc.
BioForce Nanosciences, Inc. is a wholly owned subsidiary of BioForce Nanosciences Holdings, Inc. (OTC Bulletin Board: BFNH.OB). BioForce Nanosciences is a unique development stage company entering into commercialization with over a decade of research and accomplishment in the field of bionanotechnology. The Company has demonstrated the ability to take a product from concept to commercial sale. For more information, visit www.bioforcenano.com.
This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in the Company's most recent filings with the Securities and Exchange Commission. The Company's actual results could differ materially from such forward-looking statements. We assume no duty to update these statements at any future date.
SOURCE BioForce Nanosciences, Inc.
Source: PR Newswire (December 18, 2006 - 8:30 AM EST)